ADVOCATE (2021) — Trial Summary

ADVOCATE (2021): The ADVOCATE trial evaluated avacopan, an oral selective C5a receptor inhibitor, as a treatment for ANCA-associated vasculitis, compared to prednisone.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.